Cytokinetics Stock Earnings Reports

Cytokinetics reported a strong Q1 2026 driven by the commercial launch of MYQORZO in the U.S. and positive Phase III top-line results for aficamten in nonobstructive hypertrophic cardiomyopathy (ACACIA-HCM). MYQORZO began shipping January 27 and delivered $4.8M in net product revenue in ~9 weeks, with early adoption exceeding internal expectations: ~680 patients prescribed by quarter-end (1,100 through April), >275 prescribers in Q1 (425 through April), >1,400 REMS certifications, and early new-to-brand exit share estimated >30%. US Medicare access is ~90% and commercial access is targeted to reach 50% by early Q3 and parity by end of Q4. The European Commission approved MYQORZO in February and Germany launch is planned for Q2; additional HTA dossiers and an MAA in Switzerland were filed, with Health Canada decision expected in H2. ACACIA-HCM met both co-primary endpoints (KCCQ clinical summary score and peak VO2) with statistically significant improvements versus placebo, favorable secondary endpoints (NYHA class, ventilatory efficiency/peak VO2 composite, NT-proBNP), and no new safety signals, positioning aficamten to potentially expand into nonobstructive HCM and prompting plans for regulatory engagement and an sNDA submission. Other clinical programs advanced: CAMELLIA-HCM (Japan), CEDAR-HCM (pediatrics), COMET-HF (omecamtiv mecarbil enrollment ongoing), and AMBER-HFpEF (ulacamten cohort enrollment expanded). Financials: total revenues $19.4M (vs $1.6M y/y) driven by MYQORZO product sales and a Bayer milestone; R&D $95.5M, SG&A $104.9M, net loss $206M ($1.67/share). Cash and investments ~$1.1B (down ~$144M QoQ). Company reiterated 2026 combined GAAP R&D + SG&A guidance of $830M–$870M (stock-based comp $120M–$130M) and prioritized disciplined capital allocation to support launches, pipeline advancement, and muscle-biology research. Key near-term milestones: FDA meetings regarding ACACIA-HCM, potential sNDA submission for nHCM, Germany launch in Q2, possible FDA approval of MAPLE-HCM sNDA (PDUFA Nov 14, 2026), completion of adolescent cohort enrollment in CEDAR-HCM by year-end, continued enrollment in COMET-HF and AMBER-HFpEF, and initiation of a second Phase I for CK-089.